.png)
Executive Director
The Neurodegeneration Consortium MD Anderson Cancer Center
Houston, Texas, United States
William J. Ray, PhD is the Director of The Neurodegeneration Consortium (NDC), a multi-institutional collaboration whose mission is to slow, stop, or reverse AD and related neurodegenerative diseases. The NDC is a collaboration between investigators at the Massachusetts Institute of Technology, Mt Sinai School of Medicine, and the drug discovery center based at MD Anderson Cancer Center in Houston, TX. Dr. Ray has extensive experience developing therapeutics for diseases of the nervous system, including Cerevance's Phase II Parkinson's drug CNV766, Takeda's Phase II schizophrenia drug TAK-041, and Merck's Phase II Alzheimer's drug MK-7622, and is co-Founder of Magnolia Neurosciences, Prior to joining the NDC in April 2015, Dr. Ray was Director, CNS Research at Takeda Pharmaceuticals, and led several drug discovery projects from basic research into development for schizophrenia, Parkinson’s disease, autism, and other CNS disorders. He joined Takeda in 2013 as part of their acquisition of the biotech start-up Envoy Therapeutics, where he was Senior Director and responsible for developing both a pipeline of CNS therapeutics as well as a platform technology. Prior to Envoy Therapeutics, Dr. Ray spent 11 years at Merck, where he led multiple research projects in Alzheimer’s disease. He earned his PhD from Washington University Medical School in Neuroscience
Wednesday, June 15, 2022
12:00 PM – 1:30 PM ET
Disclosure(s): No relevant financial relationship(s) with ineligible companies to disclose.
Wednesday, June 15, 2022
12:05 PM – 12:25 PM ET
Disclosure(s): No relevant financial relationship(s) with ineligible companies to disclose.
Wednesday, June 15, 2022
1:05 PM – 1:30 PM ET
Disclosure(s): No relevant financial relationship(s) with ineligible companies to disclose.